Influence of Escherichia coli Shiga Toxin on the Mammalian Central Nervous System

Advances in Applied Microbiology

Volumn 71, Issue , 2010, Pages 1-19

  Obata, Fumiko ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGA TOXIN;

ANIMAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; DISEASE MODEL; ESCHERICHIA COLI INFECTION; HUMAN; METABOLISM; MICROBIOLOGY; MOUSE; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT; RAT; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; HUMANS; MICE; RABBITS; RATS; SHIGA TOXIN; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 77952316269     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2164(10)71001-7     Document Type: Chapter

References (66)

1. Bale, J.F. Jr., Brasher, C., Siegler, R.L., CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis. Am. J. Dis. Child. 134 (1980), 869–872.
2. Banks, W.A., Robinson, S.M., Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav. Immun. 24 (2010), 102–109.
3. Bast, D.J., Brunton, J.L., Karmali, M.A., Richardson, S.E., Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits. Infect. Immun. 65 (1997), 2019–2028.
4. Boccoli, J., Loidl, C.F., Lopez-Costa, J.J., Creydt, V.P., Ibarra, C., Goldstein, J., Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains. Brain Res. 1230 (2008), 320–333.
5. Brasher, C., Siegler, R.L., The hemolytic-uremic syndrome. West. J. Med. 134 (1981), 193–197.
6. Cimolai, N., Carter, J.E., Bacterial genotype and neurological complications of Escherichia coli O157:H7-associated haemolytic uraemic syndrome. Acta Paediatr. 87 (1998), 593–594.
7. Cimolai, N., Morrison, B.J., Carter, J.E., Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics 90 (1992), 616–621.
8. Cleary, T.G., Cytotoxin-producing Escherichia coli and the hemolytic uremic syndrome. Pediatr. Clin. North Am. 35 (1988), 485–501.
9. Dean-Nystrom, E.A., Pohlenz, J.F., Moon, H.W., O'Brien, A.D., Escherichia coli O157:H7 causes more-severe systemic disease in suckling piglets than in colostrum-deprived neonatal piglets. Infect. Immun. 68 (2000), 2356–2358.
10. DiMario, F.J. Jr., Bronte-Stewart, H., Sherbotie, J., Turner, M.E., Lacunar infarction of the basal ganglia as a complication of hemolytic-uremic syndrome. MRI and clinical correlations. Clin. Pediatr. (Phila.) 26 (1987), 586–590.
11. Donohue-Rolfe, A., Kondova, I., Oswald, S., Hutto, D., Tzipori, S., Escherichia coli 0157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. J. Infect. Dis. 181 (2000), 1825–1829.
12. Fujii, J., Kita, T., Yoshida, S., Takeda, T., Kobayashi, H., Tanaka, N., Ohsato, K., Mizuguchi, Y., Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice. Infect. Immun. 62 (1994), 3447–3453.
13. Fujii, J., Kinoshita, Y., Kita, T., Higure, A., Takeda, T., Tanaka, N., Yoshida, S., Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect. Immun. 64 (1996), 5053–5060.
14. Fujii, J., Kinoshita, Y., Yamada, Y., Yutsudo, T., Kita, T., Takeda, T., Yoshida, S., Neurotoxicity of intrathecal Shiga toxin 2 and protection by intrathecal injection of anti-Shiga toxin 2 antiserum in rabbits. Microb. Pathog. 25 (1998), 139–146.
15. Fujii, J., Kinoshita, Y., Yutsudo, T., Taniguchi, H., Obrig, T., Yoshida, S.I., Toxicity of Shiga toxin 1 in the central nervous system of rabbits. Infect. Immun. 69 (2001), 6545–6548.
16. Fujii, J., Kinoshita, Y., Matsukawa, A., Villanueva, S.Y., Yutsudo, T., Yoshida, S., Successful steroid pulse therapy for brain lesion caused by Shiga toxin 2 in rabbits. Microb. Pathog. 46 (2009), 179–184.
17. Garcia, A., Marini, R.P., Feng, Y., Vitsky, A., Knox, K.A., Taylor, N.S., Schauer, D.B., Fox, J.G., A naturally occurring rabbit model of enterohemorrhagic Escherichia coli-induced disease. J. Infect. Dis. 186 (2002), 1682–1686.
18. Garcia, A., Bosques, C.J., Wishnok, J.S., Feng, Y., Karalius, B.J., Butterton, J.R., Schauer, D.B., Rogers, A.B., Fox, J.G., Renal injury is a consistent finding in Dutch Belted rabbits experimentally infected with enterohemorrhagic Escherichia coli. J. Infect. Dis. 193 (2006), 1125–1134.
19. Garcia, A., Marini, R.P., Catalfamo, J.L., Knox, K.A., Schauer, D.B., Rogers, A.B., Fox, J.G., Intravenous Shiga toxin 2 promotes enteritis and renal injury characterized by polymorphonuclear leukocyte infiltration and thrombosis in Dutch Belted rabbits. Microbes Infect. 10 (2008), 650–656.
20. Garg, A.X., Suri, R.S., Barrowman, N., Rehman, F., Matsell, D., Rosas-Arellano, M.P., Salvadori, M., Haynes, R.B., Clark, W.F., Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290 (2003), 1360–1370.
21. Gerber, A., Karch, H., Allerberger, F., Verweyen, H.M., Zimmerhackl, L.B., Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J. Infect. Dis. 186 (2002), 493–500.
22. Gianantonio, C.A., Vitacco, M., Mendilaharzu, F., Gallo, G.E., Sojo, E.T., The hemolytic-uremic syndrome. Nephron 11 (1973), 174–192.
23. Glabinski, A.R., Ransohoff, R.M., Chemokines and chemokine receptors in CNS pathology. J. Neurovirol. 5 (1999), 3–12.
24. Glabinski, A.R., Ransohoff, R.M., Sentries at the gate: Chemokines and the blood-brain barrier. J. Neurovirol. 5 (1999), 623–634.
25. Goldstein, J., Loidl, C.F., Creydt, V.P., Boccoli, J., Ibarra, C., Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: An ultrastructural study. Brain Res. 1161 (2007), 106–115.
26. Hamano, S., Nakanishi, Y., Nara, T., Seki, T., Ohtani, T., Oishi, T., Joh, K., Oikawa, T., Muramatsu, Y., Ogawa, Y., et al. Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan. Acta Paediatr. 82 (1993), 454–458.
27. Isogai, E., Isogai, H., Kimura, K., Hayashi, S., Kubota, T., Fujii, N., Takeshi, K., Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain. Infect. Immun. 66 (1998), 197–202.
28. Jeong, Y.K., Kim, I.O., Kim, W.S., Hwang, Y.S., Choi, Y., Yeon, K.M., Hemolytic uremic syndrome: MR findings of CNS complications. Pediatr. Radiol. 24 (1994), 585–586.
29. Karmali, M.A., Petric, M., Lim, C., Fleming, P.C., Arbus, G.S., Lior, H., The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151 (1985), 775–782.
30. Karpman, D., Connell, H., Svensson, M., Scheutz, F., Alm, P., Svanborg, C., The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175 (1997), 611–620.
31. Keepers, T.R., Psotka, M.A., Gross, L.K., Obrig, T.G., A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J. Am. Soc. Nephrol. 17 (2006), 3404–3414.
32. Kita, E., Yunou, Y., Kurioka, T., Harada, H., Yoshikawa, S., Mikasa, K., Higashi, N., Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7. Infect. Immun. 68 (2000), 1207–1214.
33. Kolling, G.L., Obata, F., Gross, L.K., Obrig, T.G., Immunohistologic techniques for detecting the glycolipid Gb(3) in the mouse kidney and nervous system. Histochem. Cell Biol. 130 (2008), 157–164.
34. Kurioka, T., Yunou, Y., Kita, E., Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice. Infect. Immun. 66 (1998), 1726–1734.
35. Lopez, E.L., Diaz, M., Grinstein, S., Devoto, S., Mendilaharzu, F., Murray, B.E., Ashkenazi, S., Rubeglio, E., Woloj, M., Vasquez, M., et al. Hemolytic uremic syndrome and diarrhea in Argentine children: The role of Shiga-like toxins. J. Infect. Dis. 160 (1989), 469–475.
36. Matise, I., Sirinarumitr, T., Bosworth, B.T., Moon, H.W., Vascular ultrastructure and DNA fragmentation in swine infected with Shiga toxin-producing Escherichia coli. Vet. Pathol. 37 (2000), 318–327.
37. Mayhan, W.G., Regulation of blood-brain barrier permeability. Microcirculation 8 (2001), 89–104.
38. Mizuguchi, M., Tanaka, S., Fujii, I., Tanizawa, H., Suzuki, Y., Igarashi, T., Yamanaka, T., Takeda, T., Miwa, M., Neuronal and vascular pathology produced by verocytotoxin 2 in the rabbit central nervous system. Acta Neuropathol. (Berl.) 91 (1996), 254–262.
39. Mizuguchi, M., Sugatani, J., Maeda, T., Momoi, T., Arima, K., Takashima, S., Takeda, T., Miwa, M., Cerebrovascular damage in young rabbits after intravenous administration of Shiga toxin 2. Acta Neuropathol. (Berl.) 102 (2001), 306–312.
40. Nishikawa, K., Matsuoka, K., Kita, E., Okabe, N., Mizuguchi, M., Hino, K., Miyazawa, S., Yamasaki, C., Aoki, J., Takashima, S., Yamakawa, Y., Nishijima, M., et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA 99 (2002), 7669–7674.
41. Obata, F., Tohyama, K., Bonev, A.D., Kolling, G.L., Keepers, T.R., Gross, L.K., Nelson, M.T., Sato, S., Obrig, T.G., Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J. Infect. Dis. 198 (2008), 1398–1406.
42. Okuda, T., Tokuda, N., Numata, S., Ito, M., Ohta, M., Kawamura, K., Wiels, J., Urano, T., Tajima, O., Furukawa, K., Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. Chem. 281 (2006), 10230–10235.
43. Ostroff, S.M., Tarr, P.I., Neill, M.A., Lewis, J.H., Hargrett-Bean, N., Kobayashi, J.M., Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160 (1989), 994–998.
44. Ren, J., Utsunomiya, I., Taguchi, K., Ariga, T., Tai, T., Ihara, Y., Miyatake, T., Localization of verotoxin receptors in nervous system. Brain Res. 825 (1999), 183–188.
45. Richardson, S.E., Rotman, T.A., Jay, V., Smith, C.R., Becker, L.E., Petric, M., Olivieri, N.F., Karmali, M.A., Experimental verocytotoxemia in rabbits. Infect. Immun. 60 (1992), 4154–4167.
46. Robson, W.L., Leung, A.K., Trevenen, C.L., Brant, R., Diarrhea-associated hemolytic uremic syndrome. Can. Fam. Physician 39 (1993), 2139–2145.
47. Rooney, J.C., Anderson, R.M., Hopkins, I.J., Clinical and pathologic aspects of central nervous system involvement in the haemolytic uraemic syndrome. Proc. Aust. Assoc. Neurol. 8 (1971), 67–75.
48. Sheth, K.J., Swick, H.M., Haworth, N., Neurological involvement in hemolytic-uremic syndrome. Ann. Neurol. 19 (1986), 90–93.
49. Siegler, R.L., Pavia, A.T., Christofferson, R.D., Milligan, M.K., A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 94 (1994), 35–40.
50. Siegler, R.L., Pysher, T.J., Tesh, V.L., Taylor, F.B. Jr., Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12 (2001), 1458–1467.
51. Siegler, R.L., Obrig, T.G., Pysher, T.J., Tesh, V.L., Denkers, N.D., Taylor, F.B., Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr. Nephrol. 18 (2003), 92–96.
52. Signorini, E., Lucchi, S., Mastrangelo, M., Rapuzzi, S., Edefonti, A., Fossali, E., Central nervous system involvement in a child with hemolytic uremic syndrome. Pediatr. Nephrol. 14 (2000), 990–992.
53. Steinborn, M., Leiz, S., Rudisser, K., Griebel, M., Harder, T., Hahn, H., CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings. Pediatr. Radiol. 34 (2004), 805–810.
54. Sugatani, J., Igarashi, T., Munakata, M., Komiyama, Y., Takahashi, H., Komiyama, N., Maeda, T., Takeda, T., Miwa, M., Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2. Thromb. Res. 100 (2000), 61–72.
55. Taguchi, H., Takahashi, M., Yamaguchi, H., Osaki, T., Komatsu, A., Fujioka, Y., Kamiya, S., Experimental infection of germ-free mice with hyper-toxigenic enterohaemorrhagic Escherichia coli O157:H7, strain 6. J. Med. Microbiol. 51 (2002), 336–343.
56. Takahashi, K., Funata, N., Ikuta, F., Sato, S., Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J. Neuroinflammation, 5, 2008, 11.
57. Tapper, D., Tarr, P., Avner, E., Brandt, J., Waldhausen, J., Lessons learned in the management of hemolytic uremic syndrome in children. J. Pediatr. Surg. 30 (1995), 158–163.
58. Taylor, C.M., White, R.H., Winterborn, M.H., Rowe, B., Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands. Br. Med. J. (Clin. Res. Ed.) 292 (1986), 1513–1516.
59. Taylor, F.B. Jr., Tesh, V.L., DeBault, L., Li, A., Chang, A.C., Kosanke, S.D., Pysher, T.J., Siegler, R.L., Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am. J. Pathol. 154 (1999), 1285–1299.
60. Tzipori, S., Chow, C.W., Powell, H.R., Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets. J. Clin. Pathol. 41 (1988), 1099–1103.
61. Tzipori, S., Gunzer, F., Donnenberg, M.S., de Montigny, L., Kaper, J.B., Donohue-Rolfe, A., The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect. Immun. 63 (1995), 3621–3627.
62. Upadhyaya, K., Barwick, K., Fishaut, M., Kashgarian, M., Siegel, N.J., The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 65 (1980), 115–120.
63. Verweyen, H.M., Karch, H., Allerberger, F., Zimmerhackl, L.B., Enterohemorrhagic Escherichia coli (EHEC) in pediatric hemolytic-uremic syndrome: a prospective study in Germany and Austria. Infection 27 (1999), 341–347.
64. Watanabe, M., Matsuoka, K., Kita, E., Igai, K., Higashi, N., Miyagawa, A., Watanabe, T., Yanoshita, R., Samejima, Y., Terunuma, D., Natori, Y., Nishikawa, K., Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J. Infect. Dis. 189 (2004), 360–368.
65. Zoja, C., Corna, D., Farina, C., Sacchi, G., Lingwood, C., Doyle, M.P., Padhye, V.V., Abbate, M., Remuzzi, G., Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J. Lab. Clin. Med. 120 (1992), 229–238.
66. Zotta, E., Lago, N., Ochoa, F., Repetto, H.A., Ibarra, C., Development of an experimental hemolytic uremic syndrome in rats. Pediatr. Nephrol. 23 (2008), 559–567.